Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?

Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy in hematologic malignancies (Abstracts 7503, 7504, and 7505).

Multiple Myeloma

Sagar Lonial, MD, and Paul G. Richardson, MD, on Multiple Myeloma: Expert Perspectives on Treatment Advances

Sagar Lonial, MD, of Emory University School of Medicine, and Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discuss the top presentations on multiple myeloma delivered at this year’s meeting.

Breast Cancer

Hope S. Rugo, MD, on HER2+ Breast Cancer: Findings on a Trastuzumab Biosimilar

Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III study results on a new possible alternative to trastuzumab for HER2-positive metastatic breast cancer: the biosimilar known as Myl-1401O (Abstract LBA503).

Breast Cancer

Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes

Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506). To see the French language version of this discussion, click here.

Colorectal Cancer

Alan P. Venook, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Analysis of CALGB-SWOG 80405

Alan Venook, MD, of the University of California, San Francisco, and John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, discuss the impact of primary tumor location on overall survival and progression-free survival in patients with advanced disease (Abstract 3504).

Oct

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?

Sagar Lonial, MD, and Paul G. Richardson, MD, on Multiple Myeloma: Expert Perspectives on Treatment Advances

Hope S. Rugo, MD, on HER2+ Breast Cancer: Findings on a Trastuzumab Biosimilar

Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes

Alan P. Venook, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Analysis of CALGB-SWOG 80405

Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?

FDA Approves Combination Regimen for Extensive-Stage SCLC

Amivantamab Plus Lazertinib vs Osimertinib in EGFR-Mutated Advanced NSCLC

In Extensive-Stage Small Cell Lung Cancer Novel Maintenance Regimen Boosts Overall Survival

Fertility-Sparing Surgery vs Hysterectomy for Early-Stage Cervical Cancer: Comparable Survival Rates but Higher Recurrence Risk